Multiple myeloma trials in Sweden
22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 4Taking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Lund, Uppsala
- Age
- 18 years and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - Phase 3Taking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Falun, Huddinge, Lund, Orebro
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - Phase 2Taking peopleA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Falun, Gothenburg, Lund, Stockholm, Uppsala
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07589634 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Goteborg, Huddinge, Lund
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - Phase 1/2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Boras, Goteborg, Huddinge
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - Phase 2Enrolling by invitationInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Luleå
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989 - Phase 2Taking peoplePhase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Where
- Falun, Goteborg, Huddinge, Lund, Uppsala
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-524793-42-00 · EU 2025-524793-42-00 - Phase 3Not yet taking people in SwedenA trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
- Where
- Goteborg, Huddinge, Lund
- Age
- 18 years and over
- People
- 234 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00 - No phaseTaking peopleA Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Where
- Gothenburg, Jönköping, Stockholms, Uddevalla
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Janssen-Cilag Ltd.
See details and how to joinNCT06285318 - Phase 3Taking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Boras, Falun, Goteborg, Linkoping, Luleå, Lund, Orebro
- Age
- 18 years and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - Phase 3Taking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Falun, Huddinge, Orebro
- Age
- 18 years and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - Phase 1/2Taking peopleA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Huddinge
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00 - Phase 3Taking peopleStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Gothenburg, Huddinge, Lund
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978 - Phase 1Taking peopleA Study in Leukemia Patients With Karonudib
- Where
- Huddinge, Örebro
- Age
- 18 years to 75 years
- People
- 50 worldwide
- Run by
- Thomas Helleday Foundation
See details and how to joinNCT04077307 - Phase 1/2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Boras, Goteborg, Huddinge
- Age
- 18 years and over
- People
- 88 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00 - Phase 1/2Taking peopleStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Where
- Stockholm
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- CellCentric Ltd.
See details and how to joinNCT04068597 - Phase 3Taking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Lund
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - No phaseTaking peopleReal-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
- Where
- Lund
- Age
- 18 years and over
- People
- 75 worldwide
- Run by
- Takeda
See details and how to joinNCT05879757 - Phase 2Taking peopleDiscontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
- Where
- Boras, Falun, Goteborg, Halmstad, Helsingborg, Huddinge, Jonkoping, Linkoping, Lund, Orebro, Trollhattan, Umea, Uppsala, Varberg
- Age
- 18 years and over
- People
- 200
- Run by
- Vaestra Goetalandsregionen
See details and how to join2025-524022-18-00 · EU 2025-524022-18-00 - Phase 1/2Taking peopleStudy of ODX (OsteoDex) in Multiple Myeloma
- Where
- Stockholm, Uddevalla
- Age
- 18 years and over
- People
- 12
- Run by
- DexTech Medical AB
See details and how to joinNCT06616389 - No phaseTaking peopleBortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
- Where
- Uppsala
- Age
- 18 years and over
- People
- 100
- Run by
- Uppsala University
See details and how to joinNCT06245629 - Phase 2Taking peopleClinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
- Where
- Stockholm
- Age
- 18 years and over
- People
- 62
- Run by
- Karolinska Institutet
See details and how to joinNCT04558931